Otsuka Seeks Accelerated Approval for Sibeprenlimab in IgA Nephropathy Following Positive Phase III Interim Results

Otsuka, sibeprenlimab, IgA nephropathy, Phase III trial, accelerated approval, FDA, kidney disease, autoimmune disease, APRIL antibody.

Gazyva Shows Promising Results in Lupus Nephritis Treatment, Paving Way for Expanded Indication

Gazyva, lupus nephritis, Roche, Genentech, Phase III REGENCY study, complete renal response, autoimmune disease, kidney function, end-stage kidney disease.

AstraZeneca’s Fasenra Gains FDA Approval for Eosinophilic Granulomatosis with Polyangiitis, Expanding Treatment Options for Rare Autoimmune Disease

AstraZeneca, Fasenra, FDA approval, eosinophilic granulomatosis with polyangiitis (EGPA), rare autoimmune disease, biologic treatment, asthma medication, GSK’s Nucala